Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT06910826
Starting soon Observational

Visual Education for Spinal Anesthesia Acceptance

NCT06910826 · tracked via the Priya Life Science Turkey tracker
Sponsor
Istinye University
Phase
Observational
Started
2025-04-01
Last updated
2025-04-04

Condition(s) studied

Incidence of Spinal Anesthesia Preference

Study summary

Primary outcome: To determine the incidence of spinal anesthesia preference after exposure to the visual information catalog.

Secondary outcomes: To analyze independent (age, education, profession, previous experiences) and dependent (fear, anxiety) factors influencing patient choices.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-45 * who are undergoing elective cesarean sections * and classified as ASA I-II according to the American Society of Anesthesiologists (ASA) scale Exclusion Criteria: * patients under 18 or over 45 years old, * emergency cesareans, * preeclampsia, * cardiovascular disorders, * fetal abnormalities, * those not receiving spinal anesthesia or converted to general anesthesia during surgery, * those who refuse to participate in the study, * hospital clinical or administrative staff, * patients with psychiatric disorders

Primary outcome measure(s)

  • incidence of spinal anesthesia preference — 4 MONTH
    To determine the incidence of spinal anesthesia preference after exposure to the visual information catalog

Trial sites (1)

FacilityCityRegionStatus
Istinye Üniversity Istanbul Merkez Mahallesi

More Istinye University trials in Turkey

Effects of Blood Flow Restriction Aerobic Exercise on Inflammation, Hypoxia, Exercise Capacity, and Lung Function in COPD Recruiting
Tranexamic Acid Dose and Remifentanil Titration in Septorhinoplasty Starting soon
Serum Bicarbonate Changes During Laparoscopic Bariatric Surgery Starting soon
Core Stability, Postural Balance, and Flexibility in Healthy Women: A Comparative Study Between Pilates Practitioners and Sedentary Individuals Recruiting
Awareness of Surgeons Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06910826 on ClinicalTrials.gov ↗ ← All trials in Turkey